Soma (carisoprodol) 250 mg, manufactured by Meda Pharmaceuticals Inc (Somerset, NJ), is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. The recommended dose is 250 to 350 mg 3 times a day and at bedtime. The recommended maximum duration of Soma use is up to 2 or 3 weeks.
Kapidex (dexlansoprazole) delayedrelease capsules, manufactured by Takeda Pharmaceuticals North America Inc (Deerfield, IL), recently received FDA approval for the once-daily oral treatment of heartburn associated with symptomatic, nonerosive gastroesophageal reflux disease, the healing of erosive esophagitis, and the maintenance of healed erosive esophagitis. The product is available in 30- and 60-mg capsules.
AstraZeneca (Wilmington, DE) recently received FDA approval for Symbicort (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Symbicort also is indicated for the maintenance treatment of asthma in patients 12 years and older.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs